DICOT — Dicot Pharma AB Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Dicot Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.631 | 0.021 | 0.079 | 0.12 | 0.228 |
Cost of Revenue | |||||
Gross Profit | -11 | -15.1 | -23.8 | -26.5 | -38.7 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14 | 17.6 | 27.3 | 31.8 | 45.2 |
Operating Profit | -13.3 | -17.5 | -27.2 | -31.7 | -45 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -13.4 | -17.5 | -27.2 | -31.8 | -44.2 |
Net Income After Taxes | -13.4 | -17.5 | -27.2 | -31.8 | -44.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.4 | -17.5 | -27.2 | -31.8 | -44.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.4 | -17.5 | -27.2 | -31.8 | -44.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.35 | -0.614 | -0.522 | -0.264 | -0.083 |